1. Home
  2. JFU vs SKYE Comparison

JFU vs SKYE Comparison

Compare JFU & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 9F Inc.

JFU

9F Inc.

HOLD

Current Price

$4.55

Market Cap

54.5M

Sector

Finance

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.74

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFU
SKYE
Founded
2006
2012
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.5M
44.9M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
JFU
SKYE
Price
$4.55
$0.74
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$14.75
AVG Volume (30 Days)
5.5K
233.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
86.41
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.68
52 Week High
$9.48
$5.75

Technical Indicators

Market Signals
Indicator
JFU
SKYE
Relative Strength Index (RSI) 45.29 40.95
Support Level $4.12 $0.68
Resistance Level $5.66 $0.83
Average True Range (ATR) 0.34 0.05
MACD 0.05 0.01
Stochastic Oscillator 23.78 36.18

Price Performance

Historical Comparison
JFU
SKYE

About JFU 9F Inc.

9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: